NEW YORK, Dec. 15, 2016 /PRNewswire/ -- Cantor Fitzgerald & Co., a leading global financial services firm, today announced the expansion of its Healthcare Equity Research team with the addition of Bill Tanner, Ph.D. as a Senior Research Analyst covering Biotechnology and Steven Halper as a Senior Research Analyst covering Healthcare Services. Both Bill and Steven are Managing Directors based in New York and reporting to Mara Goldstein, Director of Research at Cantor Fitzgerald.
"With the continued growth and innovation in the healthcare and biotech sectors, Cantor Fitzgerald is further expanding its thought-leadership presence and providing value for clients in these complex and dynamic sectors," said Shawn Matthews, CEO of Cantor Fitzgerald & Co.
"Thanks to an in-depth understanding of the biotech and healthcare services, Bill and Steven's addition to the team underscores Cantor Fitzgerald's commitment to enhancing its healthcare research franchise and to complementing its existing biotechnology and healthcare services coverage," added Mara Goldstein. "Cantor's healthcare team will cover a broad range of companies and activities within the sector. I am confident that their deep industry knowledge will add immediate value for clients."
Bill Tanner, Ph.D. joined the firm from Guggenheim Securities, where he was a Senior Biotechnology Analyst. Prior to Guggenheim, Bill was at Lazard Capital Markets, Leerink Swann and SG Cowen, all firms with a significant focus on the healthcare sector. In addition to Bill's 20-year tenure as a respected biotechnology analyst, he was also the Director of Research while at Leerink.
Throughout his career, Bill has covered a variety of biotechnology companies, spanning market capitalizations and therapeutic areas. Most recently, he has focused on companies developing products addressing Central Nervous System (CNS) disorders, women's healthcare and microbiome. Bill has been the recipient of a National Research Award Fellowship at Washington University School of Medicine and was a postdoctoral fellow with the Corporate Research and Development Staff at Monsanto. Bill received a Ph.D. from Texas A&M University and an MBA from the Olin School of Business at Washington University.
Prior to joining Cantor Fitzgerald, Steven Halper focused on healthcare information technology, managed care and pharmaceutical service industries at several major firms including FBR Capital Markets, and previously Lazard Capital Markets. Prior to this, Mr. Halper served for two years in this capacity at Stifel Financial and for 10 years at Thomas Weisel Partners (TWP), where he was also Associate Head of Equity Research. Before joining TWP, he was at DLJ. Mr. Halper holds a B.S. in Economics from Binghamton University and an MBA from Fordham University. Mr. Halper's research has been recognized by publications including Institutional Investor, The Wall Street Journal and Starmine.
About Cantor Fitzgerald
Cantor Fitzgerald, a leading global financial services group at the forefront of financial and technological innovation has been a proven and resilient leader for over 65 years. Cantor is a preeminent investment bank serving more than 7,000 institutional clients around the world, recognized for its strengths in fixed income and equity capital markets, investment banking, prime brokerage, and commercial real estate finance and for its global distribution platform. Cantor Fitzgerald & Co. is one of 23 primary dealers authorized to trade U.S. government securities with The Federal Reserve Bank of New York. For more information please visit www.cantor.com.
Note to Editors: Cantor Fitzgerald, L.P., led by Chairman and Chief Executive Officer Howard W. Lutnick, is the parent entity of Cantor Fitzgerald & Co., led by Chief Executive Officer Shawn P. Matthews.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cantor-fitzgerald-expands-healthcare-and-biotech-equity-research-platforms-with-addition-of-bill-tanner-phd-and-steven-halper-300379092.html
SOURCE Cantor Fitzgerald & Co.